| Advances in ovarian cancer therapy |
78 |
| Positioning of proteasome inhibitors in therapy of solid malignancies |
24 |
| Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases |
22 |
| A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer |
20 |
| A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc((TM))) in patients with locally advanced or metastatic cancer |
19 |
| Autophagy modulation: a prudent approach in cancer treatment? |
18 |
| Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting |
16 |
| A phase II study of modified FOLFIRINOX for chemotherapy-na < ve patients with metastatic pancreatic cancer |
15 |
| Cancer immunotherapy: the art of targeting the tumor immune microenvironment |
15 |
| The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis |
15 |
| The role of thioredoxin system in cancer: strategy for cancer therapy |
15 |
| LncRNA SNHG16 sponges miR-98-5p to regulate cellular processes in osteosarcoma |
14 |
| A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies |
13 |
| A phase I study of LY316 a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer |
13 |
| TGF beta receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer |
13 |
| Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis |
12 |
| Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia |
11 |
| Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis |
11 |
| The thioredoxin system and cancer therapy: a review |
11 |
| Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma |
11 |
| Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy |
10 |
| Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain |
10 |
| Disruption of CTLA-4 expression on peripheral blood CD8+T cell enhances anti-tumor efficacy in bladder cancer |
10 |
| Cytochrome P450 3A 3A and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes |
10 |
| Current status of nanomedicine in the chemotherapy of breast cancer |
10 |
| Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study |
9 |
| Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer |
9 |
| Phase 1/1b dose escalation and expansion study of BEZ a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer |
9 |
| Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines |
9 |
| Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia |
9 |
| Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma |
9 |
| Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice |
9 |
| B7-H3 in tumors: friend or foe for tumor immunity? |
9 |
| The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer |
9 |
| Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer |
9 |
| Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters |
9 |
| Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model |
8 |
| Pharmacokinetics of liposomal curcumin (Lipocurc) infusion: effect of co-medication in cancer patients and comparison with healthy individuals |
8 |
| The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer |
8 |
| Autophagy therapeutics: preclinical basis and initial clinical studies |
8 |
| Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling |
8 |
| Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83 (TM), a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach |
8 |
| Role of TPMT and ITPA variants in mercaptopurine disposition |
8 |
| Alternative dosing regimens for atezolizumab: right dose, wrong frequency |
8 |
| Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells |
8 |
| Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy |
8 |
| Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer |
8 |
| Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer |
7 |
| MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B |
7 |
| Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial |
7 |
